Cargando…

Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view

Background Since December 2019, the newly emerged SARS-CoV-2 virus continues to infect humans and many people died from severe Covid-19 during the last 2 years worldwide. Different approaches are being used for treatment of this infection and its consequences, but limited results have been achieved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Najmeddin, Ali, Bahrololoumi Shapourabadi, Mina, Behdani, Mahdi, Dorkoosh, Farid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325376/ https://www.ncbi.nlm.nih.gov/pubmed/34343644 http://dx.doi.org/10.1016/j.bbagen.2021.129974

Ejemplares similares

Expressing of Recombinant VEGFR2-specific Nanobody in Baculovirus Expression System
por: Shokrollahi, Narjes, et al.
Publicado: (2021)

Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
por: Saied, AbdulRahman A., et al.
Publicado: (2022)

SAbDab in the age of biotherapeutics: updates including SAbDab-nano, the nanobody structure tracker
por: Schneider, Constantin, et al.
Publicado: (2021)

Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function
por: Kazemi-Lomedasht, Fatemeh, et al.
Publicado: (2018)

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis
por: Karami, Elmira, et al.
Publicado: (2020)

Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein
por: Ghaderi, Hajarossadat, et al.
Publicado: (2021)

Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
por: Jafari, Mahdie, et al.
Publicado: (2022)

Designing and Development of a Tandem Bivalent Nanobody against VEGF(165)
por: Khodabakhsh, Farnaz, et al.
Publicado: (2021)

Cell-specific targeting by engineered M13 bacteriophage expressing VEGFR2 nanobody
por: Ranjibar, Farideh, et al.
Publicado: (2018)

Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability
por: Trikeriotis, Markos, et al.
Publicado: (2022)

Pharmaceutical Point of View on Parenteral Nutrition
por: Stawny, M., et al.
Publicado: (2013)

Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4)
por: Sotoudeh, Nazli, et al.
Publicado: (2021)

Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
por: Homayouni, Vida, et al.
Publicado: (2016)

In vitro combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies
por: Mohseni, Nastaran, et al.
Publicado: (2020)

In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies
por: Kazemi-Lomedasht, Fatemeh, et al.
Publicado: (2017)

In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate
por: Adyani, Seyed Masih, et al.
Publicado: (2022)

Assessment of Cytokine Expression Profile in Acute Myeloid Leukemia Patients Before and After Chemotherapy
por: Sepehrizadeh, Zargham, et al.
Publicado: (2014)

Fiber manipulation and post-assembly nanobody conjugation for adenoviral vector retargeting through SpyTag-SpyCatcher protein ligation
por: Kadkhodazadeh, Maryam, et al.
Publicado: (2022)

Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)

Integrated BioTherapeutics
por: Aman, M. Javad
Publicado: (2018)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023)

In vivo selection of novel biotherapeutics
por: Ruozi, Giulia, et al.
Publicado: (2015)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

The Emerging Biotherapeutic Agent: Akkermansia
por: Kalia, Vipin Chandra, et al.
Publicado: (2021)

Editorial: Characterization of biotherapeutic products
por: Rathore, Anurag S., et al.
Publicado: (2022)

Therapeutische Nanobodies gegen SARS-CoV-2
por: Güttler, Thomas, et al.
Publicado: (2022)

SARS-CoV-2 nanobodies 2.0
por: Labroussaa, Fabien, et al.
Publicado: (2021)

CAMEL NANOBODIES NEUTRALIZE SARS-COV-2 VARIANTS
por: Hong, Jessica, et al.
Publicado: (2023)

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006)

An Estimation of the Potential Utilization in Iranian Pharmaceutical Industry Involved in the Stock Exchange, 2008-2012
por: Annabi, Majid, et al.
Publicado: (2017)

A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies
por: Chen, Xun, et al.
Publicado: (2021)

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2
por: Mast, Fred D., et al.
Publicado: (2021)

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2021)

Generation and Characterization of a Nanobody Against SARS-CoV
por: Li, Jiang-Fan, et al.
Publicado: (2021)

Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2
por: Sun, Xin, et al.
Publicado: (2022)

Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
por: Dormeshkin, Dmitri, et al.
Publicado: (2022)

Pediatric Dosing and Body Size in Biotherapeutics
por: Shi, Rong, et al.
Publicado: (2010)

Regulatory Pathway for Licensing Biotherapeutics in Mexico
por: López-Morales, Carlos A., et al.
Publicado: (2018)

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
por: Husain, Bushra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7jdti99j4n88rqogvf3tr4i4av